Kodiak Sciences Inc. KOD has made rapid progress in the development of its lead pipeline candidate, KSI-301, a biologic therapy for treating various retinal vascular diseases. The company is ...
PALO ALTO, Calif., July 27, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results